Belger, Mark
Haro, Josep Maria
Reed, Catherine
Happich, Michael
Argimon, Josep Maria
Bruno, Giuseppe
Dodel, Richard
Jones, Roy W.
Vellas, Bruno
Wimo, Anders
Funding for this research was provided by:
Eli Lilly and Company (N/A)
Article History
Received: 12 October 2017
Accepted: 27 August 2018
First Online: 3 September 2018
Compliance with ethical standards
:
: MB, CR and MH are employees and shareholders of Eli Lilly and Company. JMH, JMA, GB, RD, RWJ, BV and AW have received financial compensation from Eli Lilly for participation in the GERAS Advisory Board. JMH has received financial compensation from Otsuka, Roche and Lundbeck for participation in advisory boards. RD has received research funding, honoraria and financial compensation for consultancy or advisory board membership from a number of pharmaceutical companies including Abbott/AbbVie, Baxter, Eli Lilly, Novartis, Octapharma and Pfizer and from some medical societies. RWJ has received honoraria for speaking at/chairing symposia and has been a member of advisory boards for Eli Lilly. AW has received financial compensation from Lundbeck, Novartis, Biogen and Roche for participation in advisory boards.
: The GERAS study was approved by ethical review boards in accordance with country-specific regulations. Written informed consent was obtained from all participants or their legal representative.